NORCROSS, Ga.--(BUSINESS WIRE)--Auriga Laboratories, Inc. (OTCBB:ARGA), a specialty pharmaceutical company formed to drive high-growth revenues through acquisition of valuable brand portfolios and innovative drug development programs, has released revenue guidance for the remainder of calendar year 2006 and for 2007, projecting significant revenue increases through sales growth of its FDA-authorized prescription drug products, including Extendryl® and other brands.
